Get the Stockscreener App
5.79
4.32%
0.24
After Hours:
5.79
Acrivon Therapeutics Inc Stock (ACRV) Forecast
The Acrivon Therapeutics Inc (ACRV) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $3.3727, representing a -41.75% decrease from the current price of $5.79. The highest analyst price target is $3.3436, and the lowest is $3.4018.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month ACRV Price Target
Average 6.372
(+10.05% Upside)
Is Acrivon Therapeutics Inc (ACRV) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 46.86 | Neutral |
| STOCH(9,6) | 45.43 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.2478 | Buy |
| ADX(14) | 8.1884 | Neutral |
| William %R | -29.17 | Neutral |
| CCI(14) | 25.08 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
5.617
Buy
|
5.6537
Buy
|
| MA20 |
5.7885
Buy
|
5.811
Sell
|
| MA50 |
6.368
Sell
|
6.3299
Sell
|
| MA100 |
7.0853
Sell
|
6.7936
Sell
|
| MA200 |
7.5383
Sell
|
6.8602
Sell
|
Buy: 3
Sell: 7
Neutral: 0
Summary: Sell
According to our latest analysis, ACRV could be considered a Moderate Sell, with 17 technical analysis indicators signaling 4 Buy signals, 8 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on ACRV, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 46.86 indicates that ACRV is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 45.43 indicates that ACRV is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that ACRV is oversold. This suggests that ACRV price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 8.1884 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 25.08 indicates that ACRV is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term ACRV price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Acrivon Therapeutics Inc financial reports and earnings history, Acrivon Therapeutics Inc (ACRV) stock could reach $34.25 by 2030, $137.38 by 2040 and $134.34 by 2050. See the projected annual prices until 2050 of the Acrivon Therapeutics Inc stock below:
- Acrivon Therapeutics Inc (ACRV) is expected to reach an average price of $78.30 in 2035, with a high prediction of $82.25 and a low estimate of $78.50. This indicates an $1,252% rise from the last recorded price of $5.79.
- Acrivon Therapeutics Inc (ACRV) stock is projected to chart a bullish course in 2040, with an average price target of $139.33, representing an $2,306% surge from its current level. The forecast ranges from a conservative $138.05 to a sky-high $137.38.
- Our analysts predict Acrivon Therapeutics Inc (ACRV) to jump 1,312% by 2045, soaring from $82.90 to an average price of $81.75, potentially reaching $87.88. While $82.90 is the low estimate, the potential upside is significant.
- Acrivon Therapeutics Inc (ACRV) stock is expected to climb by 2050, reaching an average of $129.72, a $2,140% jump from its current level. However, a wide range of estimates exists, with high and low targets of $134.34 and $129.79, respectively, highlighting the market's uncertainty.
Acrivon Therapeutics Inc Stock (ACRV) Year by Year Forecast
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2025
Acrivon Therapeutics Inc Stock (ACRV) is expected to reach an average price of $6.372 in 2025, with a high prediction of $12.40 and a low estimate of $0.3473. This indicates an +10.05% rise from the last recorded price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| February, 2025 | $3.0818 | $3.4018 | $3.3436 | -46.77% |
| March, 2025 | $2.1643 | $2.3243 | $1.9962 | -62.62% |
| April, 2025 | $2.925 | $2.5725 | $2.6159 | -49.48% |
| May, 2025 | $2.2776 | $2.7176 | $2.3932 | -60.66% |
| June, 2025 | $0.4299 | $0.7538 | $1.0399 | -92.58% |
| July, 2025 | $4.1392 | $0.3473 | $6.5473 | -28.51% |
| August, 2025 | $3.54 | $2.6511 | $5.1211 | -38.86% |
| September, 2025 | $14.35 | $10.82 | $12.40 | +147.76% |
| October, 2025 | $8.8865 | $9.2928 | $10.78 | +53.48% |
| November, 2025 | $8.3816 | $8.7916 | $8.599 | +44.76% |
| December, 2025 | $7.463 | $7.5204 | $7.9904 | +28.89% |
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2026
The predicted value for Acrivon Therapeutics Inc (ACRV) in 2026 is set at an average of $10.86. Estimates vary from a peak of $20.31 to a trough of $1.4016, indicating an +87.48% surge from the present price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $7.3081 | $7.1118 | $6.5418 | +26.22% |
| February, 2026 | $6.5232 | $6.6232 | $6.0569 | +12.66% |
| March, 2026 | $8.0783 | $6.4194 | $6.9283 | +39.52% |
| April, 2026 | $11.39 | $8.4126 | $10.76 | +96.71% |
| May, 2026 | $11.70 | $10.92 | $10.88 | +102.15% |
| June, 2026 | $9.7498 | $10.48 | $11.03 | +68.39% |
| July, 2026 | $8.9712 | $9.4087 | $9.1824 | +54.94% |
| August, 2026 | $9.1263 | $9.3363 | $9.1909 | +57.62% |
| September, 2026 | $6.2277 | $6.7177 | $8.7626 | +7.56% |
| October, 2026 | $3.9628 | $5.1128 | $5.8083 | -31.56% |
| November, 2026 | $1.8379 | $1.4016 | $3.2091 | -68.26% |
| December, 2026 | $22.01 | $1.8004 | $20.31 | +280.12% |
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Acrivon Therapeutics Inc (ACRV) is $19.55, with a high forecast of $23.76 and a low forecast of $15.34. This indicates an +237.67% increase from the last price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $21.17 | $22.47 | $23.76 | +265.57% |
| February, 2027 | $19.70 | $20.15 | $19.83 | +240.31% |
| March, 2027 | $17.08 | $19.23 | $19.25 | +194.93% |
| April, 2027 | $16.70 | $17.45 | $16.92 | +188.49% |
| May, 2027 | $15.89 | $16.74 | $16.17 | +174.46% |
| June, 2027 | $15.25 | $15.34 | $15.28 | +163.45% |
| July, 2027 | $18.28 | $15.93 | $16.13 | +215.74% |
| August, 2027 | $19.07 | $19.21 | $18.98 | +229.34% |
| September, 2027 | $18.73 | $18.92 | $18.73 | +223.50% |
| October, 2027 | $16.57 | $17.29 | $17.66 | +186.16% |
| November, 2027 | $15.99 | $16.20 | $16.10 | +176.10% |
| December, 2027 | $14.87 | $15.62 | $15.77 | +156.79% |
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2028
In 2028, Acrivon Therapeutics Inc (ACRV) is projected to reach an average price of $20.89, with a high projection of $35.12 and a low estimate of $6.6524. This indicates an +260.74% rise from the last price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $12.64 | $12.68 | $14.44 | +118.24% |
| February, 2028 | $9.8836 | $10.35 | $10.48 | +70.70% |
| March, 2028 | $6.064 | $6.6524 | $5.4757 | +4.73% |
| April, 2028 | $37.07 | $28.38 | $32.92 | +540.20% |
| May, 2028 | $30.37 | $31.50 | $35.12 | +424.53% |
| June, 2028 | $29.82 | $30.29 | $29.90 | +415.04% |
| July, 2028 | $27.60 | $27.80 | $28.83 | +376.70% |
| August, 2028 | $26.08 | $26.37 | $26.86 | +350.49% |
| September, 2028 | $24.89 | $26.30 | $25.52 | +329.94% |
| October, 2028 | $24.71 | $24.26 | $24.25 | +326.84% |
| November, 2028 | $27.69 | $25.64 | $26.88 | +378.18% |
| December, 2028 | $27.22 | $26.92 | $27.17 | +370.15% |
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2029
The 2029 price forecast for Acrivon Therapeutics Inc Stock (ACRV) is $29.09 on average, with a high prediction of $46.48 and a low estimate of $11.69. This represents an +402.38% increase from the previous price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $24.53 | $25.26 | $26.42 | +323.66% |
| February, 2029 | $23.37 | $23.52 | $23.59 | +303.62% |
| March, 2029 | $22.65 | $22.84 | $22.34 | +291.19% |
| April, 2029 | $20.78 | $21.22 | $21.81 | +258.90% |
| May, 2029 | $16.44 | $17.51 | $18.80 | +183.99% |
| June, 2029 | $11.61 | $11.90 | $14.92 | +100.57% |
| July, 2029 | $38.85 | $11.69 | $35.69 | +570.98% |
| August, 2029 | $44.56 | $45.52 | $46.48 | +669.66% |
| September, 2029 | $41.45 | $41.85 | $43.22 | +615.82% |
| October, 2029 | $39.22 | $39.97 | $40.65 | +577.37% |
| November, 2029 | $37.27 | $37.94 | $37.18 | +543.74% |
| December, 2029 | $35.90 | $36.00 | $35.67 | +519.95% |
Acrivon Therapeutics Inc Stock (ACRV) Price Forecast for 2030
Acrivon Therapeutics Inc Stock (ACRV) is expected to reach an average price of $37.24 in 2030, with a high forecast of $57.85 and a low forecast of $16.64. This signifies an +543.20% surge from the last price of $5.79.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $33.39 | $33.48 | $34.25 | +476.66% |
| February, 2030 | $33.50 | $33.18 | $33.07 | +478.61% |
| March, 2030 | $36.00 | $35.61 | $35.37 | +521.83% |
| April, 2030 | $35.10 | $34.93 | $35.18 | +506.16% |
| May, 2030 | $31.85 | $31.87 | $34.12 | +450.09% |
| June, 2030 | $29.61 | $30.41 | $30.74 | +411.45% |
| July, 2030 | $28.23 | $28.50 | $28.92 | +387.50% |
| August, 2030 | $24.12 | $24.61 | $27.13 | +316.57% |
| September, 2030 | $20.63 | $21.78 | $23.39 | +256.34% |
| October, 2030 | $16.15 | $17.05 | $19.57 | +178.85% |
| November, 2030 | $56.71 | $16.64 | $55.01 | +879.41% |
| December, 2030 | $54.64 | $55.94 | $57.85 | +843.75% |
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):